Patents by Inventor Floyd E. Romesberg

Floyd E. Romesberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210222147
    Abstract: Disclosed herein are methods, compositions and kits for the synthesis of proteins which comprises unnatural amino acids that utilize a mutant tRNA.
    Type: Application
    Filed: March 9, 2021
    Publication date: July 22, 2021
    Inventors: Jerod PTACIN, Carolina CAFFARO, Hans AERNI, Yorke ZHANG, Emil C. FISCHER, Aaron W. FELDMAN, Vivian T. DIEN, Floyd E. ROMESBERG
  • Publication number: 20200392550
    Abstract: Disclosed herein are compositions, methods, cells, engineered microorganisms, and kits for increasing the production of proteins or polypeptides comprising one or more unnatural amino acids. Further provided are compositions, cells, engineered microorganisms, and kits for increasing the retention of unnatural nucleic acids encoding the unnatural amino acids in an engineered cell, or semi-synthetic organism.
    Type: Application
    Filed: June 12, 2020
    Publication date: December 17, 2020
    Inventors: Floyd E. ROMESBERG, Vivian T. DIEN, Aaron W. FELDMAN, Rebekah J. KARADEEMA, Lingjun LI, Michael P. LEDBETTER, Anne Xiaozhou ZHOU
  • Publication number: 20200377877
    Abstract: Disclosed herein are methods, cells, engineered microorganisms, and kits for increased production of a nucleic acid molecule that comprises an unnatural nucleotide.
    Type: Application
    Filed: December 16, 2016
    Publication date: December 3, 2020
    Applicant: The Scripps Research Institute
    Inventors: Floyd E. ROMESBERG, Brian LAMB, Yorke ZHANG
  • Publication number: 20200318122
    Abstract: Disclosed herein are methods, cells, engineered microorganisms, and kits for increasing the production of polypeptides comprising one or more unnatural amino acids. Further provided are cells, engineered microorganisms, and kits for increasing the retention of unnatural nucleic acids encoding the unnatural amino acids in an engineered cell, or semi-synthetic organism.
    Type: Application
    Filed: June 26, 2020
    Publication date: October 8, 2020
    Inventors: Floyd E. ROMESBERG, Michael P. LEDBETTER, Rebekah J. KARADEEMA
  • Publication number: 20200277342
    Abstract: Disclosed herein are proteins, methods, cells, engineered microorganisms, and kits for generating a modified nucleoside triphosphate transporter from Phaeodactylum tricornutum. Also disclosed herein proteins, methods, cells, engineered microorganisms, and kits for production of a nucleic acid molecule that comprises an unnatural nucleotide utilizing a modified nucleoside triphosphate transporter from Phaeodactylum tricornutum.
    Type: Application
    Filed: April 3, 2020
    Publication date: September 3, 2020
    Inventors: Floyd E. ROMESBERG, Yorke ZHANG
  • Publication number: 20200224234
    Abstract: Disclosed herein are in vivo methods, compositions, and kits for producing nucleic acids which comprises at least one unnatural base. Disclosed herein are in vivo methods of producing a nucleic acid with an expanded genetic alphabet, the method comprising incorporatin at least one unnatural base in the nucleic acid. Disclosed herein are semi-synthetic organisms comprising an expanded genetic alphabet, wherein the genetic alphabet comprises at least one unnatural base. Disclosed herein are compositions that include a heterologous or recombinant polymerase and methods of use thereof. Further, disclosed herein are kits that are useful for stably incorporating an unnatural nucleic acid into a nucleic acid molecule, e.g., using the methods provided by the present invention in in vitro condition or under a cell free condition.
    Type: Application
    Filed: July 10, 2018
    Publication date: July 16, 2020
    Inventors: Floyd E. ROMESBERG, Yorke ZHANG, Aaron W. FELDMAN, Vivian T. DIEN
  • Patent number: 10696719
    Abstract: Disclosed herein are proteins, methods, cells, engineered microorganisms, and kits for generating a modified nucleoside triphosphate transporter from Phaeodactylum tricornutum. Also disclosed herein proteins, methods, cells, engineered microorganisms, and kits for production of a nucleic acid molecule that comprises an unnatural nucleotide utilizing a modified nucleoside triphosphate transporter from Phaeodactylum tricornutum.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: June 30, 2020
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Floyd E. Romesberg, Yorke Zhang
  • Patent number: 10696720
    Abstract: Disclosed herein are proteins, methods, cells, engineered microorganisms, and kits for generating a modified nucleoside triphosphate transporter from Phaeodactylum tricornutum. Also disclosed herein proteins, methods, cells, engineered microorganisms, and kits for production of a nucleic acid molecule that comprises an unnatural nucleotide utilizing a modified nucleoside triphosphate transporter from Phaeodactylum tricornutum.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: June 30, 2020
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Floyd E. Romesberg, Yorke Zhang
  • Publication number: 20200131555
    Abstract: Disclosed herein are methods, compositions and kits for the synthesis of proteins which comprises unnatural amino acids that utilize a mutant tRNA.
    Type: Application
    Filed: July 10, 2018
    Publication date: April 30, 2020
    Inventors: Jerod PTACIN, Carolina CAFFARO, Hans AERNI, Yorke ZHANG, Emil C. FISCHER, Aaron W. FELDMAN, Vivian T. DIEN, Floyd E. ROMESBERG
  • Patent number: 10626138
    Abstract: Provided herein are analogs of unnatural nucleotides bearing predominantly hydrophobic nucleobase analogs that form unnatural base pairs during DNA polymerase-mediated replication of DNA or RNA polymerase-mediated transcription of RNA. In this manner, the unnatural nucleobases can be introduced in a site-specific way into oligonucleotides (single or double stranded DNA or RNA), where they can provide for site-specific cleavage, or can provide a reactive linker than can undergo functionalization with a cargo-bearing reagent by means of reaction with a primary amino group or by means of click chemistry with an alkyne group of the unnatural nucleobase linker.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: April 21, 2020
    Assignees: THE SCRIPPS RESEARCH INSTITUTE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR)
    Inventors: Floyd E. Romesberg, Denis A. Malyshev, Lingjun Li, Thomas Lavergne, Zhengtao Li
  • Publication number: 20200095591
    Abstract: A recombinantly expressed nucleotide triphosphate transporter efficiently imports the triphosphates of unnatural nucleotides into cells, and the endogenous cellular machinery incorporates those nucleotides into cellular nucleic acids. UBPs can therefore form within the cell's nucleic acids. Moreover, neither the presence of the unnatural triphosphates nor the replication of the UBP represents a significant growth burden. The UBP is not efficiently excised by nucleic acid repair pathways, and therefore can be retained as long as the unnatural triphosphates are available in the growth medium. Thus, the resulting cell is the first organism to stably propagate an expanded genetic alphabet.
    Type: Application
    Filed: October 2, 2019
    Publication date: March 26, 2020
    Inventors: Floyd E. ROMESBERG, Denis A. MALYSHEV
  • Publication number: 20200040027
    Abstract: Provided herein are analogs of unnatural nucleotides bearing predominantly hydrophobic nucleobase analogs that form unnatural base pairs during DNA polymerase-mediated replication of DNA or RNA polymerase-mediated transcription of RNA. In this manner, the unnatural nucleobases can be introduced in a site-specific way into oligonucleotides (single or double stranded DNA or RNA), where they can provide for site-specific cleavage, or can provide a reactive linker than can undergo functionalization with a cargo-bearing reagent by means of reaction with a primary amino group or by means of click chemistry with an alkyne group of the unnatural nucleobase linker.
    Type: Application
    Filed: July 22, 2019
    Publication date: February 6, 2020
    Inventors: Floyd E. ROMESBERG, Denis A. MALYSHEV, Lingjun LI, Thomas LAVERGNE, Zhengtao LI
  • Publication number: 20200017540
    Abstract: Provided herein are analogs of unnatural nucleotides bearing predominantly hydrophobic nucleobase analogs that form unnatural base pairs during DNA polymerase-mediated replication of DNA or RNA polymerase-mediated transcription of RNA. In this manner, the unnatural nucleobases can be introduced in a site-specific way into oligonucleotides (single or double stranded DNA or RNA), where they can provide for site-specific cleavage, or can provide a reactive linker than can undergo functionalization with a cargo-bearing reagent by means of reaction with a primary amino group or by means of click chemistry with an alkyne group of the unnatural nucleobase linker.
    Type: Application
    Filed: August 8, 2019
    Publication date: January 16, 2020
    Inventors: Floyd E. ROMESBERG, Denis A. MALYSHEV, Lingjun LI, Thomas LAVERGNE, Zhengtao LI
  • Patent number: 10513706
    Abstract: A recombinantly expressed nucleotide triphosphate transporter efficiently imports the triphosphates of unnatural nucleotides into cells, and the endogenous cellular machinery incorporates those nucleotides into cellular nucleic acids. UBPs can therefore form within the cell's nucleic acids. Moreover, neither the presence of the unnatural triphosphates nor the replication of the UBP represents a significant growth burden. The UBP is not efficiently excised by nucleic acid repair pathways, and therefore can be retained as long as the unnatural triphosphates are available in the growth medium. Thus, the resulting cell is the first organism to stably propagate an expanded genetic alphabet.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: December 24, 2019
    Assignee: The Scripps Research Institute
    Inventors: Floyd E. Romesberg, Denis A. Malyshev
  • Publication number: 20190375803
    Abstract: Disclosed herein are proteins, methods, cells, engineered microorganisms, and kits for generating a modified nucleoside triphosphate transporter from Phaeodactylum tricornutum. Also disclosed herein proteins, methods, cells, engineered microorganisms, and kits for production of a nucleic acid molecule that comprises an unnatural nucleotide utilizing a modified nucleoside triphosphate transporter from Phaeodactylum tricornutum.
    Type: Application
    Filed: August 20, 2019
    Publication date: December 12, 2019
    Inventors: Floyd E. ROMESBERG, Yorke ZHANG
  • Publication number: 20190375802
    Abstract: Disclosed herein are proteins, methods, cells, engineered microorganisms, and kits for generating a modified nucleoside triphosphate transporter from Phaeodactylum tricornutum. Also disclosed herein proteins, methods, cells, engineered microorganisms, and kits for production of a nucleic acid molecule that comprises an unnatural nucleotide utilizing a modified nucleoside triphosphate transporter from Phaeodactylum tricornutum.
    Type: Application
    Filed: August 20, 2019
    Publication date: December 12, 2019
    Inventors: Floyd E. ROMESBERG, Yorke ZHANG
  • Publication number: 20190376054
    Abstract: Disclosed herein are methods, compositions and kits for the synthesis of proteins which comprises unnatural amino acids that utilize a mutant tRNA.
    Type: Application
    Filed: August 2, 2019
    Publication date: December 12, 2019
    Inventors: Jerod PTACIN, Carolina CAFFARO, Hans AERNI, Yorke ZHANG, Emil C. FISCHER, Aaron W. FELDMAN, Vivian T. DIEN, Floyd E. ROMESBERG
  • Publication number: 20190218257
    Abstract: Disclosed herein are proteins, methods, cells, engineered microorganisms, and kits for generating a modified nucleoside triphosphate transporter from Phaeodactylum tricornutum. Also disclosed herein proteins, methods, cells, engineered microorganisms, and kits for production of a nucleic acid molecule that comprises an unnatural nucleotide utilizing a modified nucleoside triphosphate transporter from Phaeodactylum tricornutum.
    Type: Application
    Filed: June 23, 2017
    Publication date: July 18, 2019
    Applicant: The Scripps Research Institute
    Inventors: Floyd E. ROMESBERG, Yorke ZHANG
  • Publication number: 20170029829
    Abstract: A recombinantly expressed nucleotide triphosphate transporter efficiently imports the triphosphates of unnatural nucleotides into cells, and the endogenous cellular machinery incorporates those nucleotides into cellular nucleic acids. UBPs can therefore form within the cell's nucleic acids. Moreover, neither the presence of the unnatural triphosphates nor the replication of the UBP represents a significant growth burden. The UBP is not efficiently excised by nucleic acid repair pathways, and therefore can be retained as long as the unnatural triphosphates are available in the growth medium. Thus, the resulting cell is the first organism to stably propagate an expanded genetic alphabet.
    Type: Application
    Filed: April 9, 2015
    Publication date: February 2, 2017
    Applicant: The Scripps Research Institute
    Inventors: Floyd E. ROMESBERG, Denis A. MALYSHEV
  • Publication number: 20160297851
    Abstract: Arylomycin analogs are provided, wherein the analogs can have broad spectrum bioactivity. Resistance to the antibiotic bioactivity of natural product arylomycin in a range of pathogenic bacterial species has been found to depend upon single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases), wherein the presence of a proline residue confers arylomycin resistance. Arylomycin analogs are provided herein that can overcome that resistance and provide for a broader spectrum of antibiotic bioactivity than can natural product arylomycins such as arylomycin A2. Methods for determining if a bacterial strain is susceptible to narrow spectrum arylomycin antibiotics, or if a broad spectrum analog is required for treatment, is provided. Pharmaceutical compositions and methods of treatment of bacterial infections, and methods of synthesis of arylomycin analogs, are provided.
    Type: Application
    Filed: January 28, 2016
    Publication date: October 13, 2016
    Inventors: Floyd E. Romesberg, Peter A. Smith, Tucker C. Roberts